We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.13 | -0.46% | 28.15 | 28.08 | 28.22 | 28.49 | 27.81 | 28.345 | 232,091 | 22:50:04 |
From May 2019 to May 2024
By Olivia Bugault
Bayer AG said Wednesday that it has launched a cell and gene therapy platform within its pharmaceutical division in order to speed up innovation.
"The role of Bayer's cell and gene therapy platform is to steer strategically, ensuring the different parts of the organization complement each other and combining the best in Biotech and Pharma know-how," the German chemicals and pharmaceutical conglomerate said.
The platform will complement Bayer's existing pipeline of cell and gene therapy products that comprises five assets and over fifteen preclinical candidates, the company said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
December 02, 2020 03:26 ET (08:26 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
